What was the overall market valuation for herpes zoster in Italy in 2024?

The overall market valuation for herpes zoster in Italy was $7.35 Million in 2024. Read More

What is the projected market valuation for herpes zoster in Italy by 2035?

The projected market valuation for herpes zoster in Italy is $12.75 Million by 2035. Read More

What is the expected CAGR for the Italy herpes zoster market during the forecast period 2025 - 2035?

The expected CAGR for the Italy herpes zoster market during the forecast period 2025 - 2035 is 5.13%. Read More

Which companies are the key players in the Italy herpes zoster market?

Key players in the Italy herpes zoster market include GSK, Merck & Co, Pfizer, Sanofi, AstraZeneca, Bristol-Myers Squibb, Novartis, AbbVie, and Teva Pharmaceutical Industries. Read More

What were the segment valuations for diagnosis in the Italy herpes zoster market in 2024?

In 2024, the segment valuations for diagnosis included Laboratory Testing at $1.5 Million, Immunofluorescent Microscopy at $1.0 Million, and Real-Time PCR at $1.2 Million. Read More

What is the projected valuation for antiviral medications in the treatment and prevention segment by 2035?

The projected valuation for antiviral medications in the treatment and prevention segment is expected to reach $2.5 Million by 2035. Read More

What are the expected segment valuations for the route of administration in the Italy herpes zoster market?

The expected segment valuations for the route of administration include Oral at $5.05 Million and Topical at $3.8 Million by 2035. Read More

What is the anticipated growth in the hospitals and clinics segment for herpes zoster treatment by 2035?

The anticipated growth in the hospitals and clinics segment for herpes zoster treatment is projected to reach $5.1 Million by 2035. Read More

How does the market for serological testing compare to other diagnostic methods in 2024?

In 2024, serological testing was valued at $1.0 Million, which is lower than Laboratory Testing at $1.5 Million and higher than Immunofluorescent Microscopy at $1.0 Million. Read More

What are the future prospects for the Italy herpes zoster market based on current trends?

Future prospects for the Italy herpes zoster market appear positive, with a projected increase in market valuation and a steady CAGR of 5.13% during 2025 - 2035. Read More

Italy Herpes Zoster Market

ID: MRFR/HC/51976-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

Italy Herpes Zoster Market Research Report: Size, Share, Trend Analysis By Diagnosis (Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing, Others), By Treatment and Prevention (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines, Others), By Route of Administration (Oral, Topical, Others) and By End Users (Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Diagnosis (USD Million)
  1. 4.1.1 Laboratory Testing
  2. 4.1.2 Immunofluorescent Microscopy
  3. 4.1.3 Real-Time Polymerase Chain Reaction (PCR)
  4. 4.1.4 Serological Testing
  5. 4.1.5 Others
2. 4.2 Industrial Automation & Equipment, BY Treatment and Prevention (USD Million)
  1. 4.2.1 Antiviral Medications
  2. 4.2.2 Narcotic Medications
  3. 4.2.3 Anti-Inflammatory Medications
  4. 4.2.4 Antihistamines
  5. 4.2.5 Anticonvulsants
  6. 4.2.6 Capsaicin
  7. 4.2.7 Numbing Creams, Gels, or Patches
  8. 4.2.8 Vaccines
  9. 4.2.9 Others
3. 4.3 Industrial Automation & Equipment, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Topical
  3. 4.3.3 Others
4. 4.4 Industrial Automation & Equipment, BY End User (USD Million)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Diagnostic Centers
  3. 4.4.3 Research & Academic Institutes
  4. 4.4.4 Home Care Settings
  5. 4.4.5 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GSK (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 ITALY MARKET ANALYSIS BY TREATMENT AND PREVENTION
4. 6.4 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 ITALY MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT AND PREVENTION, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT AND PREVENTION, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT AND PREVENTION, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Diagnosis (USD Million, 2025-2035)

Laboratory Testing
Immunofluorescent Microscopy
Real-Time Polymerase Chain Reaction (PCR)
Serological Testing
Others

Industrial Automation & Equipment By Treatment and Prevention (USD Million, 2025-2035)

Antiviral Medications
Narcotic Medications
Anti-Inflammatory Medications
Antihistamines
Anticonvulsants
Capsaicin
Numbing Creams, Gels, or Patches
Vaccines
Others

Industrial Automation & Equipment By Route of Administration (USD Million, 2025-2035)

Oral
Topical
Others

Industrial Automation & Equipment By End User (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Research & Academic Institutes
Home Care Settings
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”